早些时候报道，Biogen将在2025年阿尔茨海默病协会国际会议上展示48个月的LEQEMBI Clarity AD数据和皮下给药见解

2025-07-22 15:02

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued care
Presentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice